Phase III data in The Lancet show significant benefit of Novartis drug Afin

1 post / 0 new
Matthew Masterson
Matthew Masterson's picture
Phase III data in The Lancet show significant benefit of Novartis drug Afin

Phase III data in The Lancet show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC
- More than 40% of TSC patients on everolimus had their kidney tumor volume reduced by at least half with no tumor progression(1)
- Separate data show 35% of TSC patients treated with everolimus had their SEGA brain tumor volume reduced by one half or more(2)
- Tuberous sclerosis complex (TSC), a genetic disorder, may cause non-cancerous tumors to form in vital organs, including the kidney and brain(3)

EAST HANOVER, N.J., Jan. 10, 2013 /PRNewswire/ -- Data published today in The Lancet showed that patients on Afinitor® (everolimus) tablets with non-cancerous kidney tumors known as renal angiomyolipomas associated with tuberous sclerosis complex (TSC) experienced a significant reduction in tumor size and the absence of tumor progression1. Additionally, a recent issue of The Lancet featured results from a separate everolimus trial demonstrating a reduction in the size of non-cancerous brain tumors known as subependymal giant cell astrocytomas (SEGAs) associated with TSC2.
Affecting one to two million people worldwide, TSC is a genetic disorder that may cause non-cancerous tumors to form in vital organs, including the kidney and brain3. Known as Votubia® in the European Union (EU) and Switzerland for the treatment of certain patients with TSC, everolimus is the first and only medication for adult patients with these kidney tumors associated with TSC who do not require immediate surgery, and separately for pediatric and adult patients with SEGAs who require therapeutic intervention but cannot be curatively resected4,5.

For the full story please visit the link below:

http://www.hirelifescience.com/prnewswire.aspx?doc=201301101835PR_NEWS_USPR_____NY39265&showRelease=1&dir=0&industries=BIO%2CPHA%2CIDC&regions=Alabama%2CAlaska%2CArizona%2CArkansas%2CCalifornia%2CColorado%2CConnecticut%2CDelaware%2CDistrict%20of%20Columbia%2CFlorida%2CGeorgia%2CHawaii%2CIdaho%2CIllinois%2CIndiana%2CIowa%2CKansas%2CKentucky%2CLouisiana%2CMaine%2CMaryland%2CMassachusetts%2CMichigan%2CMinnesota%2CMississippi%2CMissouri%2CMontana%2CNebraska%2CNevada%2CNew%20Hampshire%2CNew%20Jersey%2CNew%20Mexico%2CNew%20York%2CNorth%20Carolina%2CNorth%20Dakota%2COhio%2COklahoma%2COregon%2CPennsylvania%2CRhode%20Island%2CSouth%20Carolina%2CSouth%20Dakota%2CTennessee%2CTexas%2CUnited%20States%20of%20America%2CUtah%2CVermont%2CVirginia%2CWashington%2CWest%20Virginia%2CWisconsin%2CWyoming&subjects=TRI%2CFDA&andorquestion=AND&&passDir=0,1